Biocryst Pharmaceuticals (BCRX) Receivables (2010 - 2026)

Biocryst Pharmaceuticals has reported Receivables for 17 years, with the latest figure at $109.3 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 17.0% year-over-year to $109.3 million; the trailing twelve-month figure through Mar 2026 stood at $109.3 million (up 17.0% YoY), and the FY2025 full-year result was $106.8 million, up 18839.36% from the prior year.
• Receivables for Q1 2026 stood at $109.3 million, up from $106.8 million in the prior quarter.
• The five-year high for Receivables was $109.3 million in Q1 2026, with the low at $564000.0 in Q4 2024.
• Historically, Receivables has averaged $49.0 million across 5 years, with a median of $48.6 million in 2023.
• The largest YoY upside for Receivables was 18839.36% in 2025 against a maximum downside of 95.32% in 2025.
• Biocryst Pharmaceuticals' Receivables stood at $41.5 million in 2022, then plunged by 94.47% to $2.3 million in 2023, then slumped by 75.44% to $564000.0 in 2024, then soared by 18839.36% to $106.8 million in 2025, then advanced by 2.3% to $109.3 million in 2026.
• The last three Receivables figures came in at $109.3 million (Q1 2026), $106.8 million (Q4 2025), and $91.3 million (Q3 2025), per Business Quant data.